Thieme, Elana
Liu, Tingting
Bruss, Nur
Roleder, Carly
Lam, Vi
Wang, Xiaoguang
Nechiporuk, Tamilla
Shouse, Geoffrey http://orcid.org/0000-0002-7917-5713
Danilova, Olga V.
Bottomly, Daniel
McWeeney, Shannon K.
Tyner, Jeffrey W.
Kurtz, Stephen E.
Danilov, Alexey V. http://orcid.org/0000-0003-4461-0970
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R50CA251708, 1R01CA244576)
Gabrielle’s Angel Foundation for Cancer Research
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Leukemia and Lymphoma Society (2319-19, 7000-18)
Leukemia and Lymphoma Society
Article History
Received: 27 June 2021
Revised: 27 January 2022
Accepted: 24 February 2022
First Online: 16 March 2022
Competing interests
: AVD has received consulting fees from AstraZeneca, Abbvie, BeiGene, Genentech, TG Therapeutics, Bayer Oncology, and Pharmacyclics and has ongoing research funding from AstraZeneca, Takeda Oncology, Bayer Oncology, Genentech, SecuraBio, MEI, TG Therapeutics, and Bristol Myers Squibb. JWT received research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Petra, Seattle Genetics, Syros, Takeda, and Tolero.
: Experiments performed with animals compiled were approved by the Institutional Animal Care and Use Committee (IACUC) of the Oregon Health and Science University. Use of patient samples was approved by Oregon Health and Science University IRB.